While the market for systemic lupus erythematosus (SLE) and lupus nephritis therapies remains dominated by generic drugs, the ...

While Roche’s Gazyva has been on the market for a dozen years and has won four approvals from the FDA, it is making a late ...

Rystiggo has interactions with some other drugs. Examples include immunoglobulins and monoclonal antibodies. An interaction occurs when one substance causes another substance to have a different ...

GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus ...

Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection. But Scripps Research scientists have now discovered that for some HIV ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection. Scientists at Scripps Research have now made a new discovery for some ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

It is notoriously hard to treat effectively. Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to ...

Meanwhile, about 47.8% of patients with another inflammatory bowel disease, namely Crohn's disease, who took this monoclonal antibody achieved an endoscopic response, compared to only 13% of those ...